Kodiak Sciences Inc. (FRA:K27)

Market Cap	1.79B +336.7%
Revenue (ttm)	n/a
Net Income	-211.82M
EPS	-3.66
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	28.22
Previous Close	28.34
Day's Range	27.89 - 28.22
52-Week Range	7.71 - 39.74
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Kodiak Sciences

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic mac...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 141
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: K27

Financial Performance

Financial numbers in USD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 19, 2026

Data Sources Report a data error